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or third line therapy settings. A phase IB study is evaluating the use 
of RAD 001 as pre-operative therapy for a brief duration followed by 
surgical resection with the intent of evaluating the molecular effects 
of this novel agent within the tumor of early stage NSCLC patients. 
The results of such studies will provide insight into the role of mTOR 
inhibitors in lung cancer therapy.
Conclusions
In addition to the agents discussed in this review, a number of agents 
that modulate other pathways including MEK, aurora kinase, C-met 
and insulin-like growth factor, are being studied for the treatment of 
various solid malignancies including NSCLC (24-27). As these agents 
enter the clinic, proper patient selection will be critical to their success. 
Clinical or molecular predictive markers that will help with patient 
selection should be evaluated as part of early phase clinical trials. With 
the increasing number of available new agents, enhancing accrual to 
clinical trials will be critical to successfully test these agents in a timely 
manner. 
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Despite incremental gains improving both the quality and length of life 
of persons with lung cancer, cure remains elusive for nearly all patients 
with metastases. The need for better treatments has never been greater. 
To meet this challenge, advances in biology and biotechnology have 
provided us with hundreds of agents appropriate for testing in patients. 
This opportunity has brought with it the challenge to select and quickly 
assess which of these potential treatments will further improve the lives 
of patients with lung cancer and maybe even affect a cure. Despite the 
importance and enormity of this task, relatively little attention has been 
paid to the process of developing therapies to combat lung cancer. 
In 1949, Karnofsky and Burchenal observed that agents that do not 
objectively shrink tumors cannot be expected to prolong life. Half a 
century of drug development has proven this assertion correct. This 
is especially true with therapies that lead to cure or dramatic beneﬁt. 
No randomized trials were necessary to prove that etoposide was a 
useful treatment in SCLC. Today, our best surrogate for survival or 
cure remains the objective documentation of the regression of tumors 
on physical exam or imaging studies. Our task is to identify how to 
document changes in lesion size more accurately and quickly. With 
rare exception, the helical CT scan is the optimal way to achieve this 
goal. It is likely that uni- or bi-dimensional CT measurements are 
reliable and reproducible within 10% or less based on a study now 
underway. Where this has been studied with both single agent geﬁtinib 
and bevacizumab, changes in lesion size exceeding this threshold can 
be documented in as little as 14 or 21 days. These facts suggest at our 
current technology allows us to replace current response standards of 
demanding 30% or 50% changes to deﬁne beneﬁt and the necessity to 
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measure shrinkage or progression months after a therapy is initiated. 
Also, electronic “rulers” and emerging automated lesion measure-
ment algorithms can routinely permit same-day response assessment. 
Coupling this to a web-based case report form can inform the treating 
physician, investigator, and sponsor of a treatment’s effect the same 
day. All this technology is in place at most medical centers and needs 
only to be applied.
The entire process can be improved in other ways as well. Clinical 
trials should not lose their focus on the primary study endpoint: dose 
(deﬁned by toxicity or effectiveness) for Phase I and effectiveness for 
Phase II. Despite our best efforts to use preclinical information to select 
and prioritize agents for testing in persons with lung cancer, most com-
pounds prove to be too toxic and/or ineffective to warrant further study. 
Knowing this unfortunate reality, expending resources for pharmacol-
ogy, correlative, and quality of life studies as part of phase I and Phase 
II trials carries with it a high likelihood of irrelevance when obtained 
from patients receiving sub-therapeutic doses in phase I, when the 
drug is shown to be toxic in phase I, or ineffective in phase II. These 
important efforts are appropriate once a safe dose and threshold of 
activity are achieved, i.e., when a sufﬁcient number if responses have 
been documented in the ﬁrst stage of a two-stage trial design. The more 
streamlined the trial, the more likely it will be to quickly accrue and 
answer the primary question posed. Biology-based therapies provide 
another opportunity to hasten drug development. Their testing permits 
the enrichment of the study group to include only those individuals 
whose tumors contain the pathway or molecule that is the target of the 
therapy. If an agent does not prove effective in these individuals, it 
usefulness in the general population of patients with lung cancer will be 
highly unlikely. Lastly, assessment of the primary study endpoint must 
be determined in real time. Any severe toxicity effects the enrollment 
of the very next person in phase I. Rapid documentation of response 
or progression can prevent the needless accrual of patients on studies 
of ineffective agents and delay in studies destined to continue while 
response data is collected.
There are additional points to consider for phase I studies. The goal of 
a phase I study is to determine a phase II dose. All other questions are 
secondary and irrelevant if the primary objective is not achieved. Rapid 
(one patient per level if no toxicity is seen) dose escalation can greatly 
hasten a phase I effort and it limits the number of patients receiving 
what eventually are proven to be sub-therapeutic dosages. Even in 
phase I, focusing on the patient group for whom the treatment was 
designed will speed the process. Volunteer studies do not facilitate this. 
The average age, concomitant medications, and co-morbid conditions 
of volunteers bear little resemblance to patients with lung cancer. In ad-
dition, volunteers are exposed to risk when they receive an anticancer 
therapy with no chance of beneﬁt. Studying new drugs in persons with 
cancer who have no therapy with a higher likelihood of beneﬁt avail-
able to them is a much better approach. For therapies where the target 
is known, even phase I trials beneﬁt from enriching the study group 
with individuals whose tumors bear the target.
For phase II trials, it is critical to use the most effective imaging 
techniques (in most cases a helical CT) to assess lesion size and to 
measure response after just one cycle or less to rule out progression 
and assess beneﬁt. For targeted therapies, initial enrollment should be 
restricted to individuals whose tumors have the target. Consideration 
should also be given to enrich for optimal indicator lesions that will 
allow the most rapid and accurate assessment of lesion size. Selecting 
the largest or selected indicator lesions (pulmonary lesions surrounded 
by aerated lung and hepatic metastases) can further improve accuracy 
and hasten the process. Each helical CT study contains a tremendous 
amount of information that should not be wasted. Uni- and bidimen-
sional measurements as well as volumetric and density determinations 
for each patient (waterfall plots) aid in making the decision whether or 
not an agent is “active”. Relying solely on “standard response criteria”. 
can be misleading. Using RECIST criteria, patients with 29% regres-
sions and 19% growth are both labeled “stable”! Ten percent regression 
or growth represents a true change using current CT technology. We 
have seen that any growth vs any regression is associated with overall 
survival, even in the relatively small number of patients included in 
phase II trials. At the very least, patients should be removed from study 
as soon as unequivocal growth has been documented. This strategy 
is in the best interest of the patient and the trial. The same is true for 
real time measurement. It makes no sense that an additional level of 
review and scrutiny (use of a reference radiologist) is routinely applied 
to measurements for the trial weeks or months after the same scan was 
measured and used to make therapeutic decisions. The most thorough 
review possible should be used for both clinical decisions and the study 
and immediately included in the on-line case report form. Alternative 
study designs (for example, adaptive designs) may also improve the 
efﬁciency of the process.
There has never been a better time to rethink how we identify new 
agents in the clinic. Imaging technology, information engineering, 
and statistical methodology advances are waiting to be applied to the 
clinical trials process. The result will be the more accurate and swift 
evaluation of the growing number anticancer therapies emerging from 
academic laboratories and the pharmaceutical industry. Only by ﬁnding 
new therapies can we break the barrier to cure.
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Cervical mediastinoscopy (CM) was ﬁrst reported in 1959 by Car-
lens.(1) For nearly 50 years it has been the cornerstone of minimally 
invasive mediastinal staging. CM remains today the gold standard 
technique to evaluate and stage the superior mediastinum by which 
new techniques are compared. It allows sampling of both paratracheal 
and tracheobronchial areas (stations 2R, 2L, 4R, 4L) as well as of the 
anterior subcarinal space (station 7). 
Accuracy: 
When discussing the accuracy of CM to evaluate of mediastinal nodal 
involvement (N2-3), false negative rates of 8-10% are often mentioned. 
In truth a large proportion of missed involved mediastinal nodes with 
CM are in nodal stations situated outside of the ﬁeld/ yield of CM such 
as in the periesophageal area(station 8). A series of 1745 consecutive 
staging CM from Barnes in St-Louis reported in 1999 described a 8% 
false negative rate, 12% of these had initially been called negative on 
frozen section analysis and 74% were found in nodal stations outside 
of the CM ﬁeld. (2) A more recent series of 1459 consecutive stag-
ing mediastinoscopies performed in between 1996 and 2005 at Duke, 
reported a false negative rate of 5.5% with 57% of missed involved 
lymph nodes located in stations 5,6,8,9, i.e. out of the ﬁeld of DM. (3) 
